Supportive Care in Cancer

, Volume 12, Issue 9, pp 619–625 | Cite as

Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies

  • Allyson J. Ocean
  • Linda T. Vahdat
Review Article


Peripheral neuropathy is a major dose-limiting side effect of many chemotherapeutic agents. The type and degree of neuropathy depend on the chemotherapy drug, dose-intensity, and cumulative dose. Disabling peripheral neuropathy has a significant negative impact on quality of life. Accordingly, a reliable assessment of chemotherapy-induced peripheral neurotoxicity is necessary, especially if potential neuroprotective agents are to be investigated. Chemoprotectants are agents that have been developed to ameliorate the toxicity associated with cytotoxic drugs. They aim to provide site-specific protection for normal tissues, without compromising antitumor efficacy. Several chemoprotectant compounds have been studied in recent clinical trials. These trials must include sufficient dose-limiting events for study and assessment of both toxicity and antitumor effect. A future avenue of investigation includes the identification of patients at higher risk for the development of peripheral neuropathy based on their genotype. Identification of these higher-risk patients may enable us to devise prevention strategies prior to the onset of this potentially debilitating complication.


Pripheral neuropathy Gutamine New treatments 


  1. 1.
    Ajani JA, Welch SR, Raber MNet al (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:47–59Google Scholar
  2. 2.
    Apfel SC (2000) Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest 18:564–573PubMedGoogle Scholar
  3. 3.
    Barohn RJ (1998) Approach to peripheral neuropathy and neuronopathy. Semin Neurol 18:7–18PubMedGoogle Scholar
  4. 4.
    Capizzi RL (1999) The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26:3–21Google Scholar
  5. 5.
    Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478–3483CrossRefPubMedGoogle Scholar
  6. 6.
    Cascinu S, Cordella L, Del Ferro E et al (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13:26–32PubMedGoogle Scholar
  7. 7.
    Casey EB, Fullerton PM, Jelliffe AW (1970) Vincristine neurotoxicity: a clinical and electrophysiological study of eighteen patients. Clin Sci 38:23P–24PGoogle Scholar
  8. 8.
    Casey EB, Jellife AM, Le Quesne PM, Millett YL (1973) Vincristine neuropathy. Clinical and electrophysiological observations. Brain 96:69–86PubMedGoogle Scholar
  9. 9.
    Chaudhry V, Chaudhry M, Crawford TO et al (2003) Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60:337–340PubMedGoogle Scholar
  10. 10.
    Chaudhry V, Rowinsky EK, Sartorius SE et al (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35:304–311PubMedGoogle Scholar
  11. 11.
    Chaudhry V, Cornblath DR, Corse A et al (2002) Thalidomide-induced neuropathy. Neurology 59:1872–1875PubMedGoogle Scholar
  12. 12.
    Colombo N, Bini S, Miceli D et al (1995) Weekly cisplatin ± glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer 5:81–86CrossRefPubMedGoogle Scholar
  13. 13.
    De Vos F (2003) A randomized phase II study of paclitaxel (P) with carboplatin (C) ± amifostine (A) as first line treatment in advanced ovarian carcinoma. Proc Amer Soc Clin Oncol 22:448Google Scholar
  14. 14.
    Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303PubMedGoogle Scholar
  15. 15.
    Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13–22Google Scholar
  16. 16.
    Fischer SJ, Podratz JL, Windebank AJ (2001) Nerve growth factor rescue of cisplatin neurotoxicity is mediated through the high affinity receptor: studies in PC12 cells and p75 null mouse dorsal root ganglia. Neurosci Lett 308:1–4CrossRefPubMedGoogle Scholar
  17. 17.
    Gelmon K, Eisenhauer E, Bryce C et al (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17:3038–3047PubMedGoogle Scholar
  18. 18.
    Gibbels E, Scheid W, Wieck HH, Kinzel W (1973) [Thalidomide neuropathy in the late stage. A clinical documentation]. Fortschr Neurol Psychiatr Grenzgeb 41:378–417PubMedGoogle Scholar
  19. 19.
    Hafstrom T (1967) Polyneuropathy after neurosedyn (thalidomide) and its prognosis. Acta Neurol Scand 43 [Suppl32]:1–41Google Scholar
  20. 20.
    Hildebrandt G, Holler E, Woenkhaus M et al (2000) Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol 11:743–747CrossRefPubMedGoogle Scholar
  21. 21.
    Hilpert F (2003) Neuroprotection with amifostine in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy-a double-blind, placebo-controlled, randomized phase II-study of the AGO Ovarian Cancer Study Group. Proc Amer Soc Clin Oncol 22:448Google Scholar
  22. 22.
    Hovestadt A, van der Burg ME, Verbiest HB et al (1992) The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol 239:143–146PubMedGoogle Scholar
  23. 23.
    Igarashi M, Thompson EI, Rivera GK (1995) Vincristine neuropathy in type I and type II Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy). Med Pediatr Oncol 25:113–116PubMedGoogle Scholar
  24. 24.
    Jacobson S, Loprinzi C (2002) Glutamine for preventing paclitaxel-associated malgias and arthralgias: unfortunately a “no go.” Proc Amer Soc Clin Oncol 1460Google Scholar
  25. 25.
    Kemp G, Rose P, Lurain J et al (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101–2112PubMedGoogle Scholar
  26. 26.
    Klimberg VS, McClellan JL (1996) Claude H. Organ, Jr. Honorary Lectureship. Glutamine, cancer, and its therapy. Am J Surg 172:418–424CrossRefPubMedGoogle Scholar
  27. 27.
    Lee RT, Oster MW, Balmaceda C et al (1999) Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel. Ann Oncol 10:1245–1247CrossRefPubMedGoogle Scholar
  28. 28.
    Links M, Lewis C (1999) Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 57:293–308CrossRefPubMedGoogle Scholar
  29. 29.
    Ma W, Eisenach JC (2002) Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 6:1037–1047CrossRefGoogle Scholar
  30. 30.
    Maestri A (2002) Acetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathy. Proc Amer Soc Clin Oncol 2807Google Scholar
  31. 31.
    McDonald ES, Windebank AJ (2002) Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 9:220–233CrossRefPubMedGoogle Scholar
  32. 32.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer, 47:207–214Google Scholar
  33. 33.
    Nakamura Y, Shimizu H, Nishijima C et al (2001) Delayed functional recovery by vincristine after sciatic nerve crush injury: a mouse model of vincristine neurotoxicity. Neurosci Lett 304:5–8CrossRefPubMedGoogle Scholar
  34. 34.
    Nozaki-Taguchi N, Chaplan SR, Higuera ES, et al (2001) Vincristine-induced allodynia in the rat. Pain 93:69–76CrossRefPubMedGoogle Scholar
  35. 35.
    Oken MM, Creech RH, Tormey DCet al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedGoogle Scholar
  36. 36.
    Parnis FX, Coleman RE, Harper PG et al (1995) A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. Eur J Cancer 31A:1721CrossRefPubMedGoogle Scholar
  37. 37.
    Peltier AC, Russell JW (2002) Recent advances in drug-induced neuropathies. Curr Opin Neurol 15:633–638CrossRefPubMedGoogle Scholar
  38. 38.
    Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509–513CrossRefPubMedGoogle Scholar
  39. 39.
    Postma TJ, Heimans JJ, Muller MJ et al (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739–744CrossRefPubMedGoogle Scholar
  40. 40.
    Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol, 249, 9–17Google Scholar
  41. 41.
    Raymond, E,Faivre, S,Woynarowski, JM,Chaney, SG (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25:4–12Google Scholar
  42. 42.
    Rowinsky EK, Eisenhauer EA, Chaudhry V et al (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15Google Scholar
  43. 43.
    Russell JW, Windebank AJ, McNiven MA et al (1995) Effect of cisplatin and ACTH4–9 on neural transport in cisplatin induced neurotoxicity. Brain Res 676:258–267CrossRefPubMedGoogle Scholar
  44. 44.
    Santini V (2001) Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother 2:479–489PubMedGoogle Scholar
  45. 45.
    Savarese D, Boucher J, Corey B (1998) Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J Clin Oncol 16:3918–3919Google Scholar
  46. 46.
    Schiller JH, Storer B, Tutsch K et al (1994) Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241–248PubMedGoogle Scholar
  47. 47.
    Schuchter LM, Hensley ML, Meropol NJ, Winer EP (2002) 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895–2903CrossRefPubMedGoogle Scholar
  48. 48.
    Smith RJ, Wilmore DW (1990) Glutamine nutrition and requirements. JPEN J Parenter Enteral Nutr 14:94S–99SPubMedGoogle Scholar
  49. 49.
    Strumberg D, Brugge S, Korn MW et al (2002) Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 13:229–236CrossRefPubMedGoogle Scholar
  50. 50.
    Tasmuth T, Hartel B, Kalso E (2002) Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 6:17–24CrossRefPubMedGoogle Scholar
  51. 51.
    Vahdat L, Papadopoulos K, Lange D et al (2001) Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192–1197PubMedGoogle Scholar
  52. 52.
    van der Hoop RG, Vecht CJ, van der Burg ME et al (1990) Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer. N Engl J Med 322:89–94PubMedGoogle Scholar
  53. 53.
    van Gerven JM, Hovestadt A, Moll JW et al (1994) The effects of an ACTH (4–9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 241:432–435PubMedGoogle Scholar
  54. 54.
    Wilson RH, Lehky T, Thomas RR (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Division of Hematology/Medical OncologyWeill Medical College of Cornell UniversityNew YorkUSA
  2. 2.New YorkUSA

Personalised recommendations